Cargando…

Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance

Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Slater, Rebecca E., Strom, Joshua G., Methawasin, Mei, Liss, Martin, Gotthardt, Michael, Sweitzer, Nancy, Granzier, Henk L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314384/
https://www.ncbi.nlm.nih.gov/pubmed/30567709
http://dx.doi.org/10.1085/jgp.201812259
_version_ 1783384095057772544
author Slater, Rebecca E.
Strom, Joshua G.
Methawasin, Mei
Liss, Martin
Gotthardt, Michael
Sweitzer, Nancy
Granzier, Henk L.
author_facet Slater, Rebecca E.
Strom, Joshua G.
Methawasin, Mei
Liss, Martin
Gotthardt, Michael
Sweitzer, Nancy
Granzier, Henk L.
author_sort Slater, Rebecca E.
collection PubMed
description Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabetic drug metformin has been associated with improved diastolic function in diabetic patients. Here we determine the therapeutic potential of metformin for improving diastolic function in a mouse model with HFpEF-like symptoms. We combine transverse aortic constriction (TAC) surgery with deoxycorticosterone acetate (DOCA) supplementation to obtain a mouse model with increased diastolic stiffness and exercise intolerance. Echocardiography and pressure–volume analysis reveal that providing metformin to TAC/DOCA mice improves diastolic function in the left ventricular (LV) chamber. Muscle mechanics show that metformin lowers passive stiffness of the LV wall muscle. Concomitant with this improvement in diastolic function, metformin-treated TAC/DOCA mice also demonstrate preserved exercise capacity. No metformin effects are seen in sham operated mice. Extraction experiments on skinned ventricular muscle strips show that the metformin-induced reduction of passive stiffness in TAC/DOCA mice is due to an increase in titin compliance. Using phospho-site-specific antibodies, we assay the phosphorylation of titin’s PEVK and N2B spring elements. Metformin-treated mice have unaltered PEVK phosphorylation but increased phosphorylation of PKA sites in the N2B element, a change which has previously been shown to lower titin’s stiffness. Consistent with this result, experiments with a mouse model deficient in the N2B element reveal that the beneficial effect of metformin on LV chamber and muscle stiffness requires the presence of the N2B element. We conclude that metformin offers therapeutic benefit during HFpEF by lowering titin-based passive stiffness.
format Online
Article
Text
id pubmed-6314384
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-63143842019-01-08 Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance Slater, Rebecca E. Strom, Joshua G. Methawasin, Mei Liss, Martin Gotthardt, Michael Sweitzer, Nancy Granzier, Henk L. J Gen Physiol Research Articles Heart failure with preserved ejection fraction (HFpEF) is a complex syndrome characterized by a preserved ejection fraction but increased diastolic stiffness and abnormalities of filling. Although the prevalence of HFpEF is high and continues to rise, no effective therapies exist; however, the diabetic drug metformin has been associated with improved diastolic function in diabetic patients. Here we determine the therapeutic potential of metformin for improving diastolic function in a mouse model with HFpEF-like symptoms. We combine transverse aortic constriction (TAC) surgery with deoxycorticosterone acetate (DOCA) supplementation to obtain a mouse model with increased diastolic stiffness and exercise intolerance. Echocardiography and pressure–volume analysis reveal that providing metformin to TAC/DOCA mice improves diastolic function in the left ventricular (LV) chamber. Muscle mechanics show that metformin lowers passive stiffness of the LV wall muscle. Concomitant with this improvement in diastolic function, metformin-treated TAC/DOCA mice also demonstrate preserved exercise capacity. No metformin effects are seen in sham operated mice. Extraction experiments on skinned ventricular muscle strips show that the metformin-induced reduction of passive stiffness in TAC/DOCA mice is due to an increase in titin compliance. Using phospho-site-specific antibodies, we assay the phosphorylation of titin’s PEVK and N2B spring elements. Metformin-treated mice have unaltered PEVK phosphorylation but increased phosphorylation of PKA sites in the N2B element, a change which has previously been shown to lower titin’s stiffness. Consistent with this result, experiments with a mouse model deficient in the N2B element reveal that the beneficial effect of metformin on LV chamber and muscle stiffness requires the presence of the N2B element. We conclude that metformin offers therapeutic benefit during HFpEF by lowering titin-based passive stiffness. Rockefeller University Press 2019-01-07 /pmc/articles/PMC6314384/ /pubmed/30567709 http://dx.doi.org/10.1085/jgp.201812259 Text en © 2018 Slater et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Articles
Slater, Rebecca E.
Strom, Joshua G.
Methawasin, Mei
Liss, Martin
Gotthardt, Michael
Sweitzer, Nancy
Granzier, Henk L.
Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title_full Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title_fullStr Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title_full_unstemmed Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title_short Metformin improves diastolic function in an HFpEF-like mouse model by increasing titin compliance
title_sort metformin improves diastolic function in an hfpef-like mouse model by increasing titin compliance
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314384/
https://www.ncbi.nlm.nih.gov/pubmed/30567709
http://dx.doi.org/10.1085/jgp.201812259
work_keys_str_mv AT slaterrebeccae metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT stromjoshuag metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT methawasinmei metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT lissmartin metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT gotthardtmichael metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT sweitzernancy metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance
AT granzierhenkl metforminimprovesdiastolicfunctioninanhfpeflikemousemodelbyincreasingtitincompliance